Enanta Pharmaceuticals (ENTA) Liabilities and Shareholders Equity (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Liabilities and Shareholders Equity of $296.87 million for fiscal Q3 2026 (quarter ended Jun 30, 2026), down 1.4% from $301.03 million a year earlier and down 5.7% from the prior quarter.
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
At the end of FY2025 (ended Sep 30, 2025), Enanta Pharmaceuticals' Liabilities and Shareholders Equity came in at $280.73 million, down 25.5% from FY2024.
- Annual Liabilities and Shareholders Equity shows a five-year compound annual growth rate of -10.4% (FY2020 to FY2025).
- In prior fiscal years, Enanta Pharmaceuticals' Liabilities and Shareholders Equity was $376.65 million in FY2024 (-18.5%), $462.28 million in FY2023 (+23.1%), $375.41 million in FY2022 (-14.4%) and $438.79 million in FY2021 (-9.7%).
- Quarterly Liabilities and Shareholders Equity has run from a low of $280.73 million in fiscal Q4 2025 to a high of $495.17 million in fiscal Q3 2023 over five years.
- On a year-over-year basis, Liabilities and Shareholders Equity has declined in each of the last nine quarters, with an average decline of 14.8% over the last eight quarters.
- The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was fiscal Q3 2023, with growth of 28.5%; the weakest was fiscal Q4 2025, with a decline of 25.5%.
- According to Business Quant data, Liabilities and Shareholders Equity for the three prior fiscal quarters was $314.7 million (Q2 2026), $329.5 million (Q1 2026) and $280.73 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Enanta Pharmaceuticals | 383.80 Mn | -344.19 Mn | - | 296.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 296.87 Mn |
| Mar 31, 2026 | 314.70 Mn |
| Dec 31, 2025 | 329.50 Mn |
| Sep 30, 2025 | 280.73 Mn |
| Jun 30, 2025 | 301.03 Mn |
| Mar 31, 2025 | 322.99 Mn |
| Dec 31, 2024 | 348.64 Mn |
| Sep 30, 2024 | 376.65 Mn |
| Jun 30, 2024 | 398.82 Mn |
| Mar 31, 2024 | 413.56 Mn |
| Dec 31, 2023 | 428.50 Mn |
| Sep 30, 2023 | 462.28 Mn |
| Jun 30, 2023 | 495.17 Mn |
| Mar 31, 2023 | 326.45 Mn |
| Dec 31, 2022 | 347.53 Mn |
| Sep 30, 2022 | 375.41 Mn |
| Jun 30, 2022 | 385.21 Mn |
| Mar 31, 2022 | 406.82 Mn |
| Dec 31, 2021 | 440.59 Mn |
| Sep 30, 2021 | 438.79 Mn |
API Access
Enanta Pharmaceuticals Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ENTA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "ENTA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ENTA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();